The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

The U.S. Food and Drug Administration extended the review of KalVista Pharmaceuticals' drug for a type of hereditary swelling ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Nucala, which is administered as a once-monthly subcutaneous injection, won its first FDA approval in 2015 as a treatment for severe asthma. The Thursday approval came later than GSK expected.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive pulmonary disease (COPD), a common lung ...

Sept 6 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive ...

The European Medicines Agency will review GSK's (GSK.L), opens new tab request to approve its asthma drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...